• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Mass Tort News

Mass Tort News

News Articles for Mass Tort Attorneys

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • News
  • LegalCast
  • Live Trials
  • Contact Us
Home / Current Litigation / FDA FINALLY MOVING ON BREAST IMPLANTS: Once again lagging behind the world in healthcare oversight

FDA FINALLY MOVING ON BREAST IMPLANTS: Once again lagging behind the world in healthcare oversight

Categories: Breast Implants, Current Litigation Tags: breast implants, current litigationOctober 25, 2019 by Mass Tort News Leave a Comment

Breast implant

(MASS TORT NEWS) U.S. health officials are now finally taking an assertive position regarding women getting breast implants by stating that stronger warnings and more details about the possible risks and complications including links to cancer. Why has there been a multi-year FDA delay on this in the USA?

The Food and Drug Administration said that manufacturers should add a warning highlighted by a “black box warning” – the most serious type – to be provided to women receiving or considering implants.

The primary makers of breast implants approved for use in the United States include:

Allergan, Inc.

Ideal Implant, Inc.

Mentor World Wide, LLC (Johnson & Johnson)

Sientra, Inc.

Melissa Shirley vs. Mentor Worldwide (J&J) Complaint USDC ND Georgia (May 15, 2017)

According to a complex analysis of FDA adverse event data, the number of suspected breast implant injuries jumped from an average of fewer than 200 a year through 2016, before the FDA’s more rigorous reporting rules, to 4,567 events in 2017 and at least 8,242 in the first half of 2018. More than 10 million women worldwide have received breast implants over the last decade, a remarkable comeback for a medical product that had suffered a crippling safety scandal and a lengthy ban in the United States.

The agency was aware of the true number of reported injuries but did not disclose them until recently. In Europe, some manufacturers have avoided reporting ruptures altogether, Dutch regulators were told. This was discovered during the  International Consortium of Investigative Journalists long term investigation titled, Implant Files investigation , which revealed the ongoing health problems plaguing many thousands of women with breast implants as part of its global research project that was released in November 2018.

https://www.cbsnews.com/news/breast-implant-recall-allergan-recalls-textured-implant-linked-to-rare-cancer-today-2019-07-24/

HOW THE FDA LAGS BEHIND THE WORLD

Australia’s Therapeutic Goods Administration (TGA) launched an effort monitor the association between breast implants and anaplastic large cell lymphoma, more than doubling the recognized number of cases identified among Australian patients between September 2016 and April 2017.

Researchers from the TGA published a study in May indicating that side effects of textured breast implants may be linked to a 14 times higher risk of ALCL in some cases.

The TGA has estimated that the breast implant lymphoma risk may be between 1-in-1,000 and 1-in-10,000, with most cases occurring between 3 and 14 years after implant, but the median being 8 years and some cases diagnosed as much as 37 years after breast surgery,

The agency is also recommending patients complete a checklist to make sure they understand all the possible side effects of the implants, such as scarring, pain, rupture and even a rare form of cancer.

“We have heard from many women that they are not fully informed of the risks when considering breast implants,” the agency said in a statement detailing the recommendations.

The agency also wants companies to explain that breast implants often require repeat surgeries and they should not be considered lifelong devices. About 1 in 5 women who get implants for cosmetic reasons need to have them removed within eight to 10 years, according to the FDA.

The agency will take public comment on the proposed guidelines before adopting them.

The new proposal is the FDA’s latest attempt to manage safety issues with the devices primarily used for breast augmentation, the most frequently performed cosmetic surgical procedure in the U.S. Roughly 400,000 patients get implants each year, 100,000 of them after cancer surgery.

As outlined Wednesday, manufacturers would not be required to adopt the boxed warning and checklist, noted Madris Tomes, a former FDA staffer. “The FDA needs to enforce the use of this and not just hope it’s used,” said Tomes, who now runs a company that analyzes device injuries and malfunctions. “Women deserve to know what is being implanted and need to know not to take these risks lightly.”

In recent years, the FDA and regulators elsewhere have grappled with a link between a rare cancer and a type of textured implant. In July, the FDA called on manufacturer Allergan to pull its Biocell implant after it was tied to heightened risk of a form of lymphoma. The company issued a worldwide recall for the implants, which had already been restricted or removed from numerous countries.

In a separate issue, the FDA has received thousands of reports from women who blame their implants for a host of health problems including rheumatoid arthritis, chronic fatigue and muscle pain. Earlier this year, the FDA held a meeting at which dozens of women urged the agency to place new warnings and restrictions on implants.

The FDA has stood by its long-standing position that the implants are essentially safe so long as women understand they can have complications. But following the meeting, the agency said women should get more explicit, understandable information about implant risks.

The devices have a silicone outer shell and are filled with either saline or silicone. The FDA’s draft guidelines recommend manufacturers clearly disclose and list their ingredients for patients.

Breast augmentation remains the most common cosmetic surgical procedure in the U.S. with more than 300,000 performed each year, according to the American Society of Plastic Surgeons.

In addition to the warning notice to Mentor Worldwide in March 2018 (above), the FDA has taken additional steps to ensure the agency is monitoring the safety and risks of breast implants. The FDA has  coordinated with the American Society of Plastic Surgeons and the Plastic Surgeons Foundation to develop the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (BIA-ALCL) Etiology and Epidemiology (PROFILE), which collects real world data regarding patients who have a confirmed diagnosis of BIA-ALCL. The data collected from this registry, have contributed to a better understanding of BIA-ALCL and FDA communication updates to the public regarding BIA-ALCL.

FDA MARCH 2019 WARNING ON IMPLANTS

  FDA News Release March 20, 2019

FDA issues warning letters to two breast implant manufacturers for failure to comply with post-approval study requirements

For Immediate Release

Today, the U.S. Food and Drug Administration issued warning letters to two breast implant manufacturers for failure to comply with their requirements, under their premarket approval orders, to conduct post-approval studies to assess the long-term safety and risks of their silicone gel-filled breast implants.

The FDA issued warning letters to Mentor Worldwide LLC of Irvine, California, and Sientra, Inc. of Santa Barbara, California.  Every manufacturer of approved silicone gel-filled breast implants is required to conduct post-approval studies to further evaluate safety and effectiveness of the products and to answer additional scientific questions about the long-term safety and potential risks of breast implants that their premarket clinical trials were not designed to answer.

“Post-approval requirements are critical to ensuring the safety and effectiveness of the medical products we regulate and we’ll continue to hold manufacturers accountable when they fail to fulfill these obligations,” said FDA Commissioner Scott Gottlieb, M.D. “We’re issuing these warning letters based on the manufacturers’ low recruitment, poor data, and low follow-up rates in their required post-approval studies. We expect these manufacturers to meet the pre-specified study requirements in order to ensure the collection of long-term data that can be used to inform long-term patient safety.  Post-approval studies, along with other surveillance tools such as adverse event reports, registries, and scientific literature, allow the FDA to help ensure the safety of medical devices and protect patients.”

The FDA’s warning letter to Mentor Worldwide LLC (Mentor) noted several serious deficiencies in the manufacturer’s post-approval study for its MemoryShape breast implant, first approved in 2013, including that the manufacturer had failed to enroll the required number of patients in the study. The action also notes Mentor had poor follow-up rates with patients in the study. Finally, the FDA notified Mentor that there were significant data inconsistencies in the study, including poor patient accounting and missing race and ethnicity data. While the FDA had concluded after reviewing several interim study reports submitted by Mentor that progress on the post-approval study appeared adequate at that time, the agency advised Mentor of concerns about patient enrollment, follow-up rates and data inconsistencies.

Mentor’s failure to address these concerns and comply with its post-approval study requirements is a violation of the firm’s pre-market approval order.

The FDA’s warning letter to Sientra, Inc. (Sientra) noted a serious deficiency in the manufacturer’s post-approval study for its Silicone Gel Breast Implants, first approved in 2013. The manufacturer had poor follow-up rates with patients. Currently, the manufacturer reported a follow-up rate of 61 percent, which is below the target follow-up rate. In the response to the manufacturer’s most recent interim study report, the FDA notified the manufacturer that the study progress was inadequate because of low follow-up rates. Sientra’s failure to address these concerns and comply with its post-approval study requirements is a violation of the firm’s pre-market approval order.

The FDA requested responses from both manufacturers within 15 working days of the issuance of the warning letters, with details about how the noted violations will be corrected. The FDA may take action for a failure to comply with post-approval orders, including pursuing applicable criminal and civil penalties, where appropriate.

The FDA’s actions today are part of the agency’s ongoing commitment to its public health mission of ensuring patient access to safe and effective medical devices. As part of the Medical Device Safety Action Plan, the FDA committed to streamlining and modernizing how the agency implements post-market actions to address device safety issues to make responses to risks more timely and effective, including taking actions against manufacturers when their post-market studies are non-compliant with any study requirements. The FDA has issued several warning letters in recent years to manufacturers who did not adequately fulfill certain postmarket study requirements, reflecting the agency’s commitment to take more aggressive actions against manufacturers who fail to comply.

In addition to the required post-approval studies, the FDA has taken additional steps to ensure the agency is monitoring the safety and risks of breast implants. For instance, FDA staff have coordinated with the American Society of Plastic Surgeons and the Plastic Surgeons Foundation to develop the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (BIA-ALCL) Etiology and Epidemiology (PROFILE), which collects real world data regarding patients who have a confirmed diagnosis of BIA-ALCL. The data collected from this registry, have contributed to a better understanding of BIA-ALCL and FDA communication updates to the public regarding BIA-ALCL.

Additionally, the FDA has worked with multiple stakeholders to facilitate the development of the National Breast Implant Registry (NBIR) to provide a platform for collecting additional real world data on the safety and performance of breast implants. This newly launched registry will greatly add to the information we collect in our own post-approval studies about the long-term safety of breast implants, and potentially enhance our understanding of the long-term safety and risks associated with breast implants.

The FDA remains committed to thoughtful, scientific, transparent, public dialogue concerning breast implant safety and effectiveness. The FDA welcomes public dialogue about breast implant safety and risk at the upcoming public meeting of the General and Plastic Surgery Devices Panel at the FDA’s headquarters in Silver Spring, Maryland on March 25-26, 2019, which will also be available via webcast.

Health care professionals and consumers should report any adverse events related to breast implants to the FDA’s MedWatch Adverse Event Reporting program.  The FDA monitors these reports and takes appropriate action necessary to ensure the safety of medical products in the marketplace.\ end of FDA notice

WHAT’S IN BREAST IMPLANTS

Shocking Ingredients Found In Dow Silicone Implants

When women are told that their implants contain silicone or saline, they often don’t tend to ask if anything else is being used alongside it. They certainly aren’t told this by the surgeons, who more than likely don’t even know themselves.

Check out the long list of alarming ingredients used in Dow’s silicone implants which came out during their court case when they were forced to disclose what was in their dangerous implants:

  • Methyl ethyl ketone (neurotoxin)
  • Cyclohexanone (neurotoxin)
  • Isopropyl Alcohol
  • Denatured Alcohol
  • Acetone (used in nail polish remover and is a neurotoxin)
  • Urethane
  • Polyvinyl chloride (neurotoxin)
  • Amine
  • Toulene
  • Dicholormethane (carcinogen)
  • Chloromethane
  • Ethyl acetate (neurotoxin)
  • Silicone
  • Sodium fluoride
  • Lead Based Solder
  • Formaldehyde
  • Talcum powder
  • Oakite (cleaning solvent)
  • Methyl 2- Cynanoacrylates
  • Ethylene Oxide (Carcinogen)
  • Xylene (neurotoxin)
  • Hexon
  • 2-Hedanone
  • Thixon-OSN-2
  • Stearic Acid
  • Zinc Oxide
  • Naptha (rubber solvent)
  • Phenol (neurotoxin)
  • Benzene (carcinogen/neurotoxin)
  • Lacquer thinner
  • Epoxy resin
  • Epoxy hardener
  • Printing Ink
  • Metal cleaning acid
  • colour pigments as release agents
  • heavy metals such as aluminium (neurotoxin linked to Alzheimer’s and auto immune disorders)
  • Platinium
  • Silica * (2)

Types of Breast Implants Used Today

Silicone Implants

Many women opt out of having silicone implants due to the Dow Corning Lawsuit. But a growing number of women are now choosing to have them again due to the implant’s ability to look more natural than other types. These implants have an elastic type envelope which is pre-filled with a sticky, clear, jelly-like form of silicone. There are a few varieties of shapes to choose from, with smooth or textured surfaces.

With the FDA allowing silicone implants to come back on the market, it is very concerning to know that statistics show (according to Nancy Bruning, author of Breast Implants — Everything You Need To Know) that almost half of all women who have this type of implant will experience a rupture within 6-10 years, and one in five women were found to have silicone migrate to other parts of their bodies.

Saline implants – silicone outer shelL

 Saline Implants

Saline implants are commonly thought to be safer, yet they have their own problems. Saline implants have a silicone shell filled with a saline water, which is salt based and ‘sterile.’ Some types are inserted empty which the surgeon will inflate during surgery with this saline liquid. There is another type of saline implant, which also has a silicone shell, but the inside contains a gel like texture. There are smooth surface saline implants and textured surface saline implants.

According to research experts, 60% of women with these types of implants have complications within four years, and one out of five require additional surgery within three years.  This seems to be a cause for concern, since patients are commonly told that implants either never need to be removed or should be removed every ten years.

Possible Side Effects

This is what your surgeon does not tell you:

  • tenderness, lumpiness, or discomfort around the implants
  • change in the shape of your breast(s)
  • change in the consistency of your breast, such as increased softness
  • change in the way your breast moves – all of these symptoms may be a sign your implant has ruptured.
  • hardening of breast tissue
  • muscle pain
  • pain and swelling of the joints
  • pain in the soft tissues
  • a burning sensation of pain
  • tightness, redness, or swelling of the skin
  • swollen glands or lymph nodes
  • unusual, extreme, or unexplained fatigue
  • swelling of the hands and feet
  • unusual hair loss
  • rashes
  • skin thickening or hardening
  • dry eyes, mouth, or vagina
  • loss of memory, mental confusion, or ‘fogginess’
  • autoimmune disorders such as fibromyalgia, rheumatoid arthritis, scleroderma, multiple chemical sensitivity disorder, cancer, and biotoxicity problems.

THE FDA FAILS AGAIN

The FDA has also posted an unusually blunt warning on its website. It advises patients that the risk of complications is high and says flatly:  “You should assume that you will need to have additional surgeries.”

 But the FDA has not required a black box safety warning. The agency said that other threats posed by breast implants — which its website lists as including “breast tissue atrophy,” “wrinkling of the implant that can be felt or seen through the skin” and “infection, including Toxic Shock Syndrome”   — are so widely known that further action was unnecessary.

Since the FDA’s decision, the breast implant business has boomed, now exceeding $1 billion in revenue a year and projected to reach $2 billion by 2025. More than 1.6 million women worldwide received cosmetic breast implants in 2017, including an estimated 345,236 in the U.S., 235,950 in Brazil, 67,478 in Mexico and 54,045 in Italy. As of 2017, breast enlargement was the most common cosmetic surgery in the world.

STAY TUNED TO MASS TORT NEWS FOR THE REST OF THE STORY ON FDA FAILURES www.masstortnews.org

Contact us at: [email protected]

Washington DC

Notice: Excerpts from previously published print and electronic media have been used in the article

Mass Tort News
Mass Tort News
masstortnews.org/
Share on Facebook Share
Share on TwitterTweet
Share on LinkedIn Share
Send email Mail

Categories: Breast Implants, Current Litigation Tags: breast implants, current litigation

Reader Interactions

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

Search

E-mail Newsletter

Sign up to receive weekly updates on the latest in Mass Tort News.

Recent Episodes

Jennifer Hoekstra and the Aylstock Witkin trial teamed the charge in more MDL Bellwether trials to verdict in the last 18 months than any prior MDL Bellwether trial track in history, showing how to fast track a trial docket and win again and again. Jennifer has been involved in direct outcomes of Bellwether trials and settlements in excess of 11 billion dollars in MDL. These dockets include leadership roles in the Proton Pump Inhibitor, Genetically Modified Rice, as well as the Actos and DePuy Pinnacle Hip Implant. She has been active in complex litigation since 2007 and shows no sign of slowing down in 2022. We look forward to watching Jennifer maintain her leadership role in the 3M Earplug mediation and settlement negations.
Leading the 3M Earplugs Bellwether Trial Victory Parade!
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LjZYdnZsek4teDVR
Diandra “Fu” Debrosse Zimmermann is managing partner of DiCello Levitt’s Birmingham office, co-managing partner of the Washington, D.C. office, and co-chair of the firm’s Mass Tort division. Fu is also a member of the firm’s Public Client, Environmental, Personal Injury, Civil Rights, and Trial practice groups.
 
Widely known for her passionate and relentless client advocacy, she represents individuals and public entities that have been injured by wrongful conduct, whether from defective medical devices or drugs, environmental contamination, corporate misconduct, or civil rights abuse. She is nationally recognized as a powerhouse in mass torts, class actions, products liability, discrimination, and sexual assault claims, and has recovered hundreds of millions of dollars in client damages. 
 
On May 27, 2022 Fu made history, becoming the first black woman ever appointed plaintiffs’ Co-Lead Counsel in a multidistrict litigation. She was appointed to the role in the massive products liability MDL, In Re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation, against two of the world’s largest manufacturers of infant formula, Abbott Laboratories (NYSE: ABT) and Mead Johnson. Comprised of more than 60 state and federal lawsuits filed across the U.S., the case stems from allegations against the manufacturers of infant formulas Similac (Abbott) and Enfamil (Mead) by parents of premature infants who were fed with that formula and developed the deadly neonatal condition, necrotizing enterocolitis (NEC). 
 
Fu currently represents individuals exposed to Paraquat, an herbicide thought to cause Parkinson’s disease. She also represents victims of civil rights violations, defective products, and other wrongful conduct. Before joining DiCello Levitt, Fu represented dozens of cities and counties in Alabama, Georgia, and Mississippi against opioid manufacturers and distributors. She has also recovered more than $30 million in damages for victims of catastrophic personal injury, product liability, employment discrimination, and civil sexual assault claims. 
 
Earlier this year, in February 2022, Fu announced that she along with Ben Crump co-founded Shades of Mass, an organization aimed at combatting the lack of diverse attorney leadership in lawsuits that disproportionately impact communities of color. Through collaboration, shared resources, education and networking opportunities, and pressure on our profession, Shades of Mass aims to rectify this inequity and achieve the diversity missing in mass tort and complex litigation case leadership. Learn more about Shades of Mass, its mission, its board members, and its board members here: https://www.law.com/2022/02/28/new-gr.... The organization will be hosting a conference in October 2023 in Atlanta. Visit the Shades of Mass website: http://www.shadesofmass.org/, to learn more. 
 
She is well-known for her relentless and compassionate client advocacy which is only matched by her passion to make this world a better place for the generations to come. Fu has extensive experience handling complex litigation, including pharmaceutical, medical device, environmental contamination, and civil rights matters. And she has earned quite a few accolades for her work, including Top 40 Under 40 attorneys (National Trial Lawyers), Top 10 Under 40 attorney for the State of Alabama (National Academy of Personal Injury Attorneys, Inc.), The National Trial Lawyers: Top 100, one of America’s Top 100 High Stakes Litigators®, and selected as a Top Woman Attorney (B-Metro magazine). 
 
Read more about Fu here: https://dicellolevitt.com/attorney/di.... 


Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass...
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews...
Fu Zimmermann Sound Bite Building a Legacy Through Leadership
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LnJyT01tMTRpNENj
Richard “Rick” Meadow is the National Mass Tort Leader as well as the Director of Business Development for The Lanier Law Firm. His responsibilities include overseeing all the firm’s pharmaceutical mass tort litigation in addition to promoting, recruiting, and maintaining associated outside relationships at a national level. Rick has represented the rights of individuals who have been injured by pharmaceuticals, medical devices, asbestos, medical malpractice, defective products, construction defects, lead poisoning, and motor vehicles, as well as the negligence of premises owners and municipalities for over 30 years. He further has extensive experience in the representation of large national insurance companies as an insurance defense attorney. This experience provides a 360-degree perspective of the practice of tort law in the United States. 
Rick has developed an extensive practice in mass tort and aggregate litigation. He has been nominated and selected to a variety of leadership positions by both his peers and courts across the country. He has served in leadership positions in many cases that have resulted in nationwide settlements. 
Rick has been working with Mark Lanier for over 30 years and is an integral part of the Lanier Trial Academy Master Class. This year’s Lanier Trial Academy 6.0; https://laniertrialacademy.com/home, will take place on June 20-23, 2022 in Houston Texas. The program includes a third day and more content, including non-verbal cues, voir dire, examinations, and openings and closings. Check out the agenda here, and if you haven’t already, register here: https://myportal.force.com/LanierTrialAcademy/s/lt-event?id=a1U3m00000Ov12TEAR&site=a0d1N000006V1VMQA0#/loginReg!  
 
Read more about Rick here: https://www.lanierlawfirm.com/attorneys/richard-d-meadow/. 
 
Remember to subscribe and follow us on social media… 

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Rick Meadow, Everybody Knows Your Name
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LkE1SWV2anhKY0lj
Diandra “Fu” Debrosse Zimmermann is managing partner of DiCello Levitt’s Birmingham office, co-managing partner of the Washington, D.C. office, and co-chair of the firm’s Mass Tort division. Fu is also a member of the firm’s Public Client, Environmental, Personal Injury, Civil Rights, and Trial practice groups.
 
Widely known for her passionate and relentless client advocacy, she represents individuals and public entities that have been injured by wrongful conduct, whether from defective medical devices or drugs, environmental contamination, corporate misconduct, or civil rights abuse. She is nationally recognized as a powerhouse in mass torts, class actions, products liability, discrimination, and sexual assault claims, and has recovered hundreds of millions of dollars in client damages. 
 
On May 27, 2022 Fu made history, becoming the first black woman ever appointed plaintiffs’ Co-Lead Counsel in a multidistrict litigation. She was appointed to the role in the massive products liability MDL, In Re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation, against two of the world’s largest manufacturers of infant formula, Abbott Laboratories (NYSE: ABT) and Mead Johnson. Comprised of more than 60 state and federal lawsuits filed across the U.S., the case stems from allegations against the manufacturers of infant formulas Similac (Abbott) and Enfamil (Mead) by parents of premature infants who were fed with that formula and developed the deadly neonatal condition, necrotizing enterocolitis (NEC). 
 
Fu currently represents individuals exposed to Paraquat, an herbicide thought to cause Parkinson’s disease. She also represents victims of civil rights violations, defective products, and other wrongful conduct. Before joining DiCello Levitt, Fu represented dozens of cities and counties in Alabama, Georgia, and Mississippi against opioid manufacturers and distributors. She has also recovered more than $30 million in damages for victims of catastrophic personal injury, product liability, employment discrimination, and civil sexual assault claims. 
 
Earlier this year, in February 2022, Fu announced that she along with Ben Crump co-founded Shades of Mass, an organization aimed at combatting the lack of diverse attorney leadership in lawsuits that disproportionately impact communities of color. Through collaboration, shared resources, education and networking opportunities, and pressure on our profession, Shades of Mass aims to rectify this inequity and achieve the diversity missing in mass tort and complex litigation case leadership. Learn more about Shades of Mass, its mission, its board members, and its board members here: https://www.law.com/2022/02/28/new-group-to-promote-attorneys-of-color-in-mass-torts/. The organization will be hosting a conference in October 2023 in Atlanta. Visit the Shades of Mass website: http://www.shadesofmass.org/, to learn more. 
 
She is well-known for her relentless and compassionate client advocacy which is only matched by her passion to make this world a better place for the generations to come. Fu has extensive experience handling complex litigation, including pharmaceutical, medical device, environmental contamination, and civil rights matters. And she has earned quite a few accolades for her work, including Top 40 Under 40 attorneys (National Trial Lawyers), Top 10 Under 40 attorney for the State of Alabama (National Academy of Personal Injury Attorneys, Inc.), The National Trial Lawyers: Top 100, one of America’s Top 100 High Stakes Litigators®, and selected as a Top Woman Attorney (B-Metro magazine). 
 
Read more about Fu here: https://dicellolevitt.com/attorney/diandra-fu-debrosse-zimmermann/. 


Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Building a Legacy Through Leadership
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LjMxeC13OVJQcjdB
John Uustal and the Kelly Uustal Law Firm are a complex personal injury firm based in Fort Lauderdale FL, who are actively involved in traumatic and catastrophic injury litigation and Mass Torts as local trial counsel for certain MDL leadership firms. Also, KU is one of the premier tobacco litigation firms in the country, securing hundreds of millions of dollars in verdicts against Big Tobacco. Never afraid to face corporate bad conduct, John Uustal and the Kelly Uustal firm will take the fight directly to the corporate boardrooms.

Check out John Uustal's blog to stay up-to-date on corporate treachery: https://www.johnuustal.com/
888.522.6601
https://www.kulaw.com

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Calling Out Boardroom Misconduct in the Courts and Court of Public Opinion
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3Lk03TENRN0s0X3cw
Today we're joined by Majed Nachawati, founder of the Fears Nachawati firm. Majed is well known as a prominent complex commercial litigator in the mass tort space and a leadership firm in emerging torts. Majed's firm is known for representing both individuals and governmental entities in dockets such as the opioid litigation, PFAS water contamination, and other major mass torts. Today we will be discussing three of the most relevant and prominent dockets in the legal world that impact both the plaintiff and defense bar. 

We engage in direct discussions on the Bayer/ Monsanto US Supreme Court appeal in the Hardeman Roundup verdict, originating in California State Court. Recently the US Solicitor General submitted a brief to the Supreme Court advising that the US Department of Justice and other federal agencies are not in favor of participating in the Monsanto- Hardeman appeal.

We then go into the Johnson & Johnson Talcum Powder MDL and related state court litigation where J&J is using the Texas Two-Step legal process to file bankruptcy, related to their talcum powder liabilities, which are expected to exceed $12 billion. Majed is also a member of the J&J bankruptcy creditor's committee.   

Majed also discusses his lead role in the Texas winter freeze litigation, where the Texas Utility Power Commission and the power grid tragically failed the citizens of Texas and numerous lives were lost, properties were destroyed and damaged. Fears Nachawati was in a leadership role from the outset of the Texas winter freeze litigation, when they filed the first lawsuit within one week of the freeze taking place. The claims in this docket relate to the catastrophic failure of the utility and regulatory entity within the state of Texas to properly ensure the safety of its citizens. Majed clearly states that it is his position in the Texas winter freeze, Monsanto roundup, and the Johnson and Johnson talcum powder litigation to be an assertive representative of firm clients in these dockets to hold the corporate parties accountable for the ongoing and embedded bad conduct, which is clearly evident in the media and now being shown in a court of law.

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Fighting Bad Conduct in America's Boardrooms
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LldJbmlZQ0VkM0Fn
John K. Rabiej served as the Deputy Director of the Bolch Judicial Institute for one year, and as the Director of the Duke Law Center for Judicial Studies for seven years. The Duke Law Center brings together judges, lawyers, researchers, government officials and other parties to advance the study and understanding of the judicial process and generate ideas for how it might be improved. During his time as the Director of the Duke Law Center, Mr. Rabiej studied the impact of technology on the judiciary, including analyzing his concerns that the courts are not keeping pace with the rapid advancement of technology in the culture at large. Prior to joining the Duke Law Center, Mr. Rabiej served as the Executive Director and Director of Judicial Outreach for The Sedona Conference; the Chief of the Rules Committee Support Office; and the American Law Institute. He presently sits on the Chief Justice’s Rules Advisory Commission, North Carolina (term ending December 31, 2023). In this episode of LegalCast, Mr. Rabiej discusses a legal bipartisan review of mass torts, class action, and the ever-expanding e-discovery quagmire that seems to be firmly embedded in complex litigation coming to a peak in 2022.  Will the plaintiffs and defense leadership be able to collaborate to reign in the ever-expanding high cost of litigation? Mr. Rabiej has made a career of working to bring opposing groups together to discuss common interests as a means to increase efficiencies in litigations. And, with millions of dollars at stake, why not at least start the discussions.

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Is Judicial Review On The Horizon?
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LmlkM1ZiUVJMYkdZ
Stephen P New. of Beckley West Virginia is one of the country’s leading opioid litigators, by bringing the fight directly to Opioid Big Pharma's doorstep. Steve and the Opioid Justice Team have been defending and advocating for the rights of the neonatal abstinence syndrome afflicted infants, aka the "NAS Babies." Who are the truly innocent victims of the now decades-old opiate crisis in America.

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Leading the Fight for Opioid Addicted Infants
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LnhNbHdDSGU3ZzZZ
George Haj is a Pulitzer-Prize winning editor who founded Haj Media in 2017. Haj Media is a strategic communications firm focusing on crisis communications, media relations, and litigation support for law firms and corporate clients. Prior to launching his own consulting firm, George spent three decades working in some of the nation’s largest news organizations. He has deep roots in the media industry and connections with reporters and editors in a range of publications across the country. George worked as executive business editor at the Miami Herald and then was a top editor at the Houston Chronicle. He also served as editorial director of ALM Media, where he directed a global newsroom of more than 100 journalists and oversaw iconic brands including The American Lawyer and National Law Journal. He can be reached at george@hajmedia.com. Find him on Twitter: https://twitter.com/georgehaj, LinkedIn: https://www.linkedin.com/in/george-haj-25ba481, and at http://www.hajmedia.com/. 

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Crisis Management & Media Training for Lawyers
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LmhvVDk2Q2MxUnpR
With four decades of experience in legal advertising with a passion for legal marketing, intake, and conversion, Harlan Schillinger has more than earned his title as the Grandfather of Legal Advertising. 

Harlan was the first in the industry to produce and market TV advertising for the legal community. In 1975, along with his partners, Harlan founded the first syndication TV production firm for high-end retailers and Lawyers, creating television commercials that aired throughout North America.

Since the late 1970s, Harlan has worked aggressively, productively, and professionally within the legal advertising space. He has said that: “Creating opportunities and increasing market share for advertising law firms is [his] #1 priority. The value of the case is everything in such a crowded market.” Harlan privately consults with lawyers who not only share his values, but who also share his vision of increasing business, being accountable, and obtaining high-value cases. His approach to intake and conversion rests on complete accountability within that area and he is known to practice what he preaches. Harlan has trademarked within the legal advertising world the two phrases that have become his backbone of philosophy: What You Don't Know, You Don't Know® and Ambassador of First Impressions™.

Since that time, Harlan has worked with more than 130 law firms in almost 100 markets throughout North America. Before joining Network Affiliates in 1985, Harlan was a founding partner and VP of Madison, Muyskens & Jones, a Connecticut-based advertising agency. In April 2016 Harlan retired from Colorado-based Network Affiliates, the nation's first and largest full-service legal advertising agency, where he was the leader of their attorney marketing efforts for over 34 years.

A few years ago, Harlan and two of his partners – Dino Colombo Esq. and Eric Coffman – developed Lead Docket, software for intake and conversion within law firms. Harlan says that Lead Docket helps law firms increase control and management of intake and conversion, allowing the firms to thrive.

Harlan is involved with a number of professional organizations, being a member of the National Trial Lawyers Executive Summit Committee as well as a Senior Editor and Writer for the National Trial Lawyers Magazine. He also has a passion for riding and building custom motorcycles, and is a proud member of the most prestigious motorcycle group in the world: Hamsters USA ® Motorcycle Group.

Learn more about Harlan at http://www.harlanschillinger.com/. 
And to check out the book he recommends – How to Win Friends & Influence People by Dale Carnegie and originally published in 1936 click here: https://www.amazon.com/How-Win-Friends-Influence-People/dp/0671027034. 

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Prep Like a Pro: Legal Networking Tips & Tricks
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LjJJRW9MWUh1UkZ3
Load More... Subscribe

Popular Tags

current litigationopioid crisisconsumer protectioncovid-19zantacemerging tortspurdue pharmaeventparaquatgeneral news

Footer

Search

Main Navigation

  • Home
  • News
  • LegalCast
  • Live Trials
  • Contact Us

Categories

Events

Trial Lawyers Summit 2022

February 16, 2022 By Mass Tort News

2021 Trial Lawyers Summit Recap

May 11, 2021 By Mark York

2021 TRIAL LAWYERS SUMMIT

May 4, 2021 By Mass Tort News

More Posts from this Category

MASS TORT NEWS

Latest Mass Tort Litigation News

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Copyright © 2022 · Mass Tort News · All Rights Reserved.